-- イムテップ社（ASX:IMM）は、軟部組織肉腫治療薬候補であるエフチラギモドアルファが、米国食品医薬品局（FDA）から希少疾病用医薬品指定を受けたことを、水曜日にオーストラリア証券取引所に提出した書類で明らかにした。 切除可能な軟部組織肉腫患者を対象に、放射線療法およびキイトルーダとの併用療法としてエフチラギモドアルファを評価する医師主導の第II相EFTISARC-NEO試験は、主要評価項目を達成し、腫瘍の硝子化/線維化の中央値は51.5%であった。 同社の株価は、水曜日の直近の取引で41%急騰した。
Related Articles
US Markets
Kweichow Moutai's Q1 Profit Edges Up as Revenue Grows 6.5%
Kweichow Moutai's (SHA:600519) attributable profit edged up 1.5% to 27.2 billion yuan in the first quarter from 26.8 billion yuan in the year-ago period, according to a Saturday filing with the Shanghai Stock Exchange.Earnings per share at the Baijiu wine manufacturer increased to 21.76 yuan from 21.38 yuan in the prior-year period.Operating revenue grew 6.5% year over year to 53.9 billion yuan from 50.6 billion yuan, in line with forecasts from Huachuang Securities.Of the figure, its Moutai-branded liquor reached 46 billion yuan, up 5.6% year over year, while its other series brands saw sales of 7.88 billion yuan, up 12% during the period.Direct selling revenue grew 27% to 29.5 billion yuan, while wholesale agent sales slid 11% year over year to 24.4 billion yuan.Its Moutai 1935 and Wangzi products gained market share due to a boost in promotions and sales, Huachuang said in its note.For its part, Jefferies forecasts the company will grow its market share in the premium baijiu segment due to online and offline integration and distributor incentives.Total operating costs rose to 17.2 billion yuan from 14.4 billion yuan in the prior-year period.Tax expenses jumped to 8.23 billion yuan from 7.16 billion yuan, the filing said.The gross margin slid 2.2 percentage points year over year due to lower prices on high-value-added products at the start of the year as well as a decline in shipments, Huachuang said in its note.Meanwhile, Kweichou Moutai's results indicate stabilizing demand for luxury goods in China, Jefferies said in a note Monday.A rebound in retail sales over the past four to six months could indicate a return to positive sales, the investment bank said in its note.For 2026, Jefferies forecasts earnings per share to slide 7% year over year to 72.56 yuan, while revenue could fall 6% year over year to 186.2 billion yuan.
$SHA:600519
Research
Rothschild & Co Redburn Upgrades Rollins to Buy From Neutral, Adjusts PT to $66 From $51.90
Rollins (ROL) has an average rating of overweight and mean price target of $65.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ROL
Research
Arete Research Upgrades Fortinet to Buy From Sell, Adjusts Price Target to $104 From $83
Fortinet (FTNT) has an average rating of hold and mean price target of $88.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$FTNT